Yasmin Karimi

13PUBLICATIONS
90CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsImmunology not elsewhere classifiedRadiation and matter
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 20, 2026
Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

|Aug 05, 2026
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

|Jul 29, 2025
Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Jonathan Weiss, Shannon A Carty, Yasmin H Karimi

|Jul 15, 2025
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Taylor R Brooks, Emily C Zabor, Yohanna B Bedelu

|Jun 09, 2025
Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.

Meng-Hsuan Lin, Jonathan Weiss, Tycel J Phillips

|Jan 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.

Joshua D Brody, Judit Jørgensen, David Belada

Pageof 3

Frequent Collaborators

5 joint publications

Joshua D Brody

3 joint publications

Umberto Vitolo

3 joint publications

Lorenzo Falchi

3 joint publications

Stephen D Smith